z-logo
Premium
Economic burden of relapsed or refractory multiple myeloma: Results from an international trial
Author(s) -
Robinson Don,
Orlowski Robert Z.,
Stokes Michael,
He Jianming,
Huse Samuel,
Chitnis Abhishek,
Kranenburg Britte,
Lam Annette
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12876
Subject(s) - absenteeism , medicine , indirect costs , quality of life (healthcare) , multiple myeloma , multivariate analysis , clinical trial , physical therapy , randomized controlled trial , family medicine , nursing , business , accounting , management , economics
Objective The direct cost of relapsed or refractory multiple myeloma ( RRMM ) is documented; indirect costs are being explored. Healthcare payers seek cost‐offsets from therapies that improve clinical outcomes but challenge budgets; employers seek lower absenteeism and better productivity. Study goals were to: (i) identify direct and indirect economic factors of RRMM , and (ii) explore longitudinal relationships between clinical, economic, and health‐related quality of life ( HRQ oL) assessments. Methods Economic questionnaire, clinical, and HRQ oL data from a multisite, international, randomized, controlled study in RRMM were analyzed. Results Patients (n=263) were 53.6% male, 91.6% Caucasian; mean age of 62.9 years, median Eastern Cooperative Oncology Group status of 1 (56.3%). Moderate to severe pain or fatigue was reported by 30.4% and 70.6%, respectively. At baseline, ≥1 hospitalization was reported by 107 (41.8%); 182 (71.1%) and 86 (33.6%) reported specialist and family physician visits, respectively. A total of 28 (10.8%) were working: 10 (37.0%) of which reported RRMM ‐driven absenteeism ≥1 day. Of those who were not working, 110 (48.2%) indicated that it was due to RRMM . Multivariate modeling showed lower hospitalization with a major tumor response (β=−1.44, CI : −2.89 to 0.01, P =.05). Conclusions Substantial RRMM indirect, social costs were observed. Better major tumor response may reduce hospital visits.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here